Our research project at a glance
Cancer cells must double their protein content before dividing (proliferation), and both cancer and surrounding cells (especially cancer-activated fibroblasts) synthetize and secrete proteins critical for tumor growth, metastasis spreading and resistance to treatment. Our group searches how protein synthesis and related signaling pathways are regulated in healthy cells, how they become altered in malignant tumors and whether they can be targeted for therapeutic intervention.
Through biochemical, cellular and in vivo models our fundamental objective is to understand how mRNA translation into protein is regulated. The function of both global (through canonical translation initiation complexes) and mRNA-specific translational factors and their respective regulations by selective signaling pathways are explored. These new mechanistic insights are then very helpful in searching whether and how alterations in the control of protein synthesis play a role in oncogenesis and in resistance to treatment.
Thanks to collaborations with clinicians and local and international industrial partners, the uncovered mechanisms are validated in patient samples and known or new pharmaceutical compounds are tested for their therapeutic potential.
We have a solid background in pancreatic tumors (and accumulating evidence in acute myeloid leukemia) showing that selective translational regulators and/or signaling pathways appears as attractive therapeutic targets. Their targeting can affect tumor growth, metastatic spreading or response to conventional treatments through either direct effects on cancer cells or indirect effects on tumor microenvironment.
- Protein synthesis
- mRNA translation
- Signaling pathways
- Tumor microenvironment
- Pancreatic cancer
- Acute myeloid leukemia
Labels and networks
Grants and funders
Oncotarget, 7 (27), pp. 41584-41598, 2016, ISSN: 1949-2553 (Electronic) 1949-2553 (Linking).
Gastroenterology, 148 (7), pp. 1452-65, 2015, ISSN: 1528-0012 (Electronic) 0016-5085 (Linking).
EMBO Mol Med, 7 (6), pp. 735-53, 2015, ISSN: 1757-4684 (Electronic) 1757-4676 (Linking).
Oncogene, 33 (15), pp. 1934-44, 2014, ISSN: 1476-5594 (Electronic) 0950-9232 (Linking).
Oncogene, 33 (11), pp. 1367-74, 2014, ISSN: 1476-5594 (Electronic) 0950-9232 (Linking).
Anti-oncogenic potential of the eIF4E-binding proteins Journal Article
Oncogene, 32 (6), pp. 671-7, 2013, ISSN: 1476-5594 (Electronic) 0950-9232 (Linking).
Mol Cell Biol, 32 (5), pp. 1004-16, 2012, ISSN: 1098-5549 (Electronic) 0270-7306 (Linking).
Mol Cell Biol, 30 (4), pp. 1097-105, 2010, ISSN: 1098-5549 (Electronic) 0270-7306 (Linking).
EMBO J, 28 (22), pp. 3514-22, 2009, ISSN: 1460-2075 (Electronic) 0261-4189 (Linking).
Proc Natl Acad Sci U S A, 106 (42), pp. 17769-74, 2009, ISSN: 1091-6490 (Electronic) 0027-8424 (Linking).